Company Overview and News
New Zealand shares dropped, led lower by Comvita as its possible takeover failed, with A2 Milk continuing last week's losses and Kiwi Property Group dropping on its earnings.
New Zealand shares rose as Goodman Property Trust's joint venture with GIC sold seven buildings in downtown Auckland, and as Ryman Healthcare chalked up another record profit. A2 Milk Co and Comvita fell.
New Zealand shares rose, led by A2 Milk Co and Synlait Milk while Pushpay fell after annual earnings met its guidance, disappointing some upbeat investors.
New Zealand shares fell as A2 Milk Co disappointed investors with a market update, dragging down partner Synlait Milk.
Mark Lister, head of private wealth research at Craigs Investment Partners, said the announcement of Fletcher's place in the MSCI Index is due out today and we will know the result tomorrow.
New Zealand shares rose, joining a regional rally, as investors predict whether an upcoming MSCI index review will spur major activity next week. Fletcher Building, which could exit the index, gains, while new addition a2 Milk Co fell.
New Zealand shares were mixed, with A2 Milk pulling the index up while Gentrack Group, Spark New Zealand and banking stocks dropped.
Spark New Zealand is selling half of its Connect 8 services infrastructure unit to electricity distributor Electra Group, in a deal which will see Connect 8 take full ownership of Electra's telecommunication's contractor Sky Communications.
New Zealand shares gained, with Gentrack Group hitting a record and electricity companies Mercury New Zealand and Contact Energy gaining.
New Zealand shares gained, led by Fisher & Paykel Healthcare Corp and Kathmandu in broad-based buying.
New Zealand shares gained in light trading as Fletcher Building's discounted rights issue and upcoming MSCI New Zealand index review weighed on investors' minds. Trade Me and Metlifecare increased while Comvita dropped.
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.
New Zealand shares fell in relatively subdued trading, led by Ebos Group, Ryman Healthcare, Air New Zealand and Fletcher Building. Comvita fell after a profit warning while A2 Milk gained on news of a deal in South Korea.
Spark New Zealand Ltd (ASX:SPK) has secured the rights to bring to New Zealanders coverage of Rugby World Cup 2019 and other world rugby tournaments.
Overseas telecom firms remained at the top by gains this month as North American telcos were mid-bound in analyst 1yr. targeting.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET